JOHN KAMPHAUS: Open Payments
NPI 1013924257 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$483 in 28 payments from 10 companies in 2025. Trend: 2023 $242 · 2024 $449 · 2025 $483
Food & beverage: $483
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $159 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Neurocrine BioSciences, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, TRINTELLIX, REXULTI, FANAPT, Jornay PM, Azstarys.
Industry payments across TX — which companies pay providers there.
